Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Faron Pharmaceuticals (FARN)

Price 170.00p on 20-02-2025 at 17:30:02
Change 0.00p 0%
Buy 175.00p
Sell 165.00p
Buy / Sell FARN Shares
Last Trade: Sell 500.00 at 166.00p
Day's Volume: 14,014
Last Close: 170.00p
Open: 170.00p
ISIN: FI4000153309
Day's Range 167.50p - 170.00p
52wk Range: 89.00p - 270.00p
Market Capitalisation: £190m
VWAP: 167.22942p
Shares in Issue: 112m

Recent Trades History Faron Pharmaceuticals (FARN)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 500 166.00p Ordinary
15:22:33 - 20-Feb-25
Buy* 588 168.00p Ordinary
15:15:13 - 20-Feb-25
Buy* 1 170.00p SI Trade
12:44:37 - 20-Feb-25
Buy* 290 168.00p Ordinary
11:49:38 - 20-Feb-25
Buy* 3 170.00p Ordinary
11:46:29 - 20-Feb-25
Unknown* 10,000 167.00p Negotiated Trade
09:46:02 - 20-Feb-25
Sell* 614 165.08p Ordinary
11:16:00 - 20-Feb-25
Buy* 5 170.00p Ordinary
10:40:32 - 20-Feb-25
Buy* 2,000 169.00p Ordinary
10:04:35 - 20-Feb-25
Buy* 3 170.00p Ordinary
09:58:38 - 20-Feb-25

Share Price History for Faron Pharmaceuticals

Time period:
to
Date Open High Low Close Volume

Share News for Faron Pharmaceuticals

UK earnings, trading statements calendar - next 7 days

20th Feb 2025 14:16

Read More

Faron Pharmaceuticals raises EUR12 million from oversubscribed placing

6th Feb 2025 11:41

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has raised EUR12 million from an oversubscribed placing ahead of upcoming trial results. Read More

IN BRIEF: Faron Pharmaceuticals shares up as presents data on Bexmab

10th Dec 2024 14:31

Faron Pharmaceuticals PLC on Tuesday - Turku, Finland-based developer of cancer immunotherapies - Presents full analysis of positive phase 2 interim data from Bexmab trial at the annual meeting of the Society of Hematology in San Diego. Faron highlights an overall response rate of 80% in refractory or relapsed HMA failed MDS patient population. HMA stands for hypomethylating agents, while MDS stands for myelodysplastic syndromes. Chief Executive Officer Juho Jalkanen says: "With this compelling evidence, we are well positioned to advance to the full phase 2 efficacy readout and actively pursue further regulatory interactions to navigate and refine the pivotal pathway for BLA filing." Read More

Faron announces promising findings from blood cancer drug trial

27th Nov 2024 11:29

(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday reported positive data from an ongoing trial on patients receiving a new treatment for a rare blood cancer. Read More

Faron Pharma shares surge as US FDA grants fast track designation

27th Aug 2024 11:08

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its loss widened in the first half of 2024, as the company successfully advanced the development of its flagship bexmarilimab treatment. Read More

FTSE 100 Latest
Value8,662.97
Change-49.56

Login to your account

Forgot Password?

Not Registered